|
www.aurobindo.com |
|
|
Hyderabad, December 11th, 2006 |
|
|
MEB
Netherlands approves
Simvastatin tablets of Aurobindo. |
|
|
|
Aurobindo Pharma Limited (Reuters
Code: ARBN.BO) is delighted to announce that
it has received the marketing authorization
approval from Medicines Evaluation Board (MEB),
NETHERLANDS for Simvastatin 5, 10, 20, 40 and 80
mg tablets. |
|
This is the third formulation
approval received from MEB, NETHERLANDS for a
product developed in house by Aurobindo, and
fifth such approval in Europe as a whole. With
this approval, it will be easier for Aurobindo
to obtain similar marketing authorization for
Simvastatin tablets in the other countries of
the European Union through Mutual Recognition
Procedure. |
|
Simvastatin is a lipid-lowering
agent belonging to a class of medications called
HMG-COA reductase inhibitors. |
|
Aurobindo has already filed 26
products in various EU countries, some of which
are nearing the marketing authorization
approvals. Many more filings in the EU countries
are in pipeline in the coming year. |
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. The company’s robust
product portfolio is spread over 6 major
therapeutic/product areas encompassing
(Antibiotics, Anti-Retrovirals, CVS/ Statins/Diabetology,
CNS, Gastro/Uro/Kidney therapeutics, Anti
fungal/ allergics/respiratory) around 65
Betalactam APIs and 123 Non-Betalactam APIs.
The Company markets its products
in over 100 countries. The company has filed
over 65 ANDAs and 88 DMFs for the USA market, in
addition to several filings in other countries.
The company has received approvals for several
facilities from leading regulatory agencies like
US FDA, UK MHRA, WHO, Health Canada, MCC South
Africa. |
For further information,
please contact:
Investor Relations
Aurobindo Pharma Limited
Plot # 2, Maitri Vihar | Ameerpet
Hyderabad - 500 038 |India
Phone (Board): +91 40 5572 5000
Email : ir@aurobindo.com |
|
|
|
|
|
|
|
|
|
PRESS
ROOM
